Morbus Parkinsonianus (Latin Wikipedia)

Analysis of information sources in references of the Wikipedia article "Morbus Parkinsonianus" in Latin language version.

refsWebsite

Global rank Latin rank

99nih.gov

4^th place

12^th place

22wikipedia.org

low place

22doi.org

2^nd place

35^th place

3wiley.com

222^nd place

175^th place

1hieronymus.us.com

low place

7,798^th place

1books.google.com

3^rd place

2^nd place

1alcuinus.net

low place

14^th place

1stetoskop.info

low place

169^th place

1springer.com

274^th place

269^th place

1ovid.com

low place

7,799^th place

1futuremedicine.com

low place

7,800^th place

1movementdisorders.org

low place

7,801^st place

1tandfonline.com

507^th place

304^th place

1parkinsonnet.info

low place

7,802^nd place

1elsevier.es

7,063^rd place

7,803^rd place

1michaeljfox.org

low place

7,804^th place

alcuinus.net

ephemeris.alcuinus.net

Lydia Ariminensis, "PRAEMIUM NOBELIANUM DE ARTE MEDICA TRIBUTUM ESSE Vir scientificus Iaponicus Praemio Nobeliano exornatus est cum autofagiam cellularum repperisset," Ephemeris, 10 Iunii 2016: "inter quos morbus Parkinsonianus."

books.google.com

Neues Latein-Lexikon - Lexicon recentis latinitatis: Über 15.000 Stichwörter der heutigen Alltagssprache in lateinischer Übersetzung(Libraria Editoria Vaticana, 1 Decembris 2011): "Parkinsonsche Krankheit, f Parkinsonianus morbus, m."

doi.org

Espay A. J., Kalia L. V., Gan-Or Z., Williams-Gray C. H., Bedard P. L., Rowe S. M., Morgante F., Fasano A., Stecher B., Kauffman M. A., et al. (Mar 2020). "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?". Neurology 94 (11): 481-94 doi:10.1212/WNL.0000000000009107
Kalia L. V., Lang A. E. (August 2015). "Parkinson's disease". Lancet 386 (9996): 896-912 doi:10.1016/S0140-6736(14)61393-3
Kim C.Y., Alcalay R.N. (Apr 2017). "Genetic Forms of Parkinson's Disease". Seminars in neurology 37 (2): 135-46 doi:10.1055/s-0037-1601567
Cook L., Schulze J., Kopil C., Hastings T., Naito A., Wojcieszek J., Payne K., Alcalay R. N., Klein C., Saunders-Pullman R., Simuni T., Foroud T. (Feb 2021). "Genetic Testing for Parkinson Disease: Are We Ready?". Neurology. Clinical practice 11 (1): 69-77 doi:10.1212/CPJ.0000000000000831
Pereira S. L., Grossmann D., Delcambre S., Hermann A., Grünewald A. (Iun 2023). "Novel insights into Parkin-mediated mitochondrial dysfunction and neuroinflammation in Parkinson's disease". Current opinion in neurobiology doi:10.1016/j.conb.2023.102720
Mizuno Y. (Oct 2020). "More than 20 years of the discovery of Park2". Neuroscience research doi:10.1016/j.neures.2020.02.002
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (Oct 1998). "The ubiquitin pathway in Parkinson's disease". Nature 395 (6701): 451-2 doi:10.1038/26652
Healy, D. G., Abou-Sleiman, P. M., Casas, J. P., Ahmadi, K. R., Lynch, T., Gandhi, S., Muqit, M. M. K., Foltynie, T., Barker, R., Bhatia, K. P., et al. (Apr 2006). "UCHL-1 is not a Parkinson's disease susceptibility gene". Annals of neurology 59 (4): 627-33 doi:10.1002/ana.20757
Nielsen P. Y. Ø., Okarmus J., Meyer M. (Feb 2023). "Role of Deubiquitinases in Parkinson's Disease-Therapeutic Perspectives". Cells 12 (4): 651 doi:10.3390/cells12040651
Svensson E., Horváth-Puhó E., Thomsen R. W., Djurhuus J. C., Pedersen L., Borghammer P., Sørensen H. T. (Oct 2015). "Vagotomy and subsequent risk of Parkinson's disease". Annals of neurology (4): 522-9 doi:10.1002/ana.24448
Lysen T. S., Darweesh S. K. L., Ikram M. K., Luik A. I., Ikram M. A. (Iul 2019). "Sleep and risk of parkinsonism and Parkinson's disease: a population-based study". Brain 142 (7): 2013-22 doi:10.1093/brain/awz113
Jo S., Kim Y.-J., Park K. W., Hwang Y. S., Lee S. H., Kim B. J., Chung S. J. (Iul 2021). "Association of NO2 and Other Air Pollution Exposures With the Risk of Parkinson Disease". JAMA neurology 78 (7): 800-8 doi:10.1001/jamaneurol.2021.1335
Pinto S., Ghio A., Teston B., Viallet F. (2010). "La dysarthrie au cours de la maladie de Parkinson. Histoire naturelle de ses composantes : dysphonie, dysprosodie et dysarthrie". Revue neurologique 166 (10): 800-10 doi:10.1016/j.neurol.2010.07.005
Bhidayasiri R., Phuenpathom W., Tan A. H., Leta V., Phumphid S., Chaudhuri K. R., Pal P. K. (Aug 2022). "Management of dysphagia and gastroparesis in Parkinson's disease in real-world clinical practice - Balancing pharmacological and non-pharmacological approaches". Frontiers in Aging Neuroscience 14 doi:10.3389/fnagi.2022.979826
Sakakibara R., Panicker J., Finazzi-Agro E., Iacovelli V., Bruschini H., et al. (Iun 2016). "A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders". Neurourology and urodynamics 35 (5): 551-63 doi:10.1002/nau.22764
Knudsen K., Krogh K., Østergaard K., Borghammer P. (2017 month=Ian). "Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives". Movement disorders 32 (1): 94-105 doi:10.1002/mds.26866
Patterson L., Rushton S. P., Attems J., Thomas A. J,, Morris C. M. (Iul 2019). "Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders". Brain pathology (4): 544-57 doi:10.1111/bpa.12697
Nyholm D., Lennernäs H. (Feb 2008). "Irregular gastrointestinal drug absorption in Parkinson's disease". Expert Opinion on drug metabolism & toxicology 4 (2): 193-203 doi:10.1517/17425255.4.2.193
Chaudhuri K. R., Poewe W., Brooks D. (Iul 2018). Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. 33. pp. 909-19 doi:10.1002/mds.27386
Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. (Ian 2007). "Valvular heart disease and the use of dopamine agonists for Parkinson's disease". The New England journal of medicine 356 (1): 39-46 doi:10.1056/NEJMoa054830
Gray R., Patel S., Ives N., Rick C., Woolley C., Muzerengi S., Gray A., Jenkinson C., McIntosh E., Wheatley K. et al. (Februarius 2022). "Long-term Effectiveness of Adjuvant Treatment with Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared with Dopamine Agonists among Patients with Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial". JAMA Neurology 79 (2): 131-40 . doi:10.1001/jamaneurol.2021.4736.
Lu C.-S., Chang H.-C., Weng Y.-H., Chen C.-C., Kuo Y.-S., Tsai Y.-C. (Iun 2021). "The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson's Disease: A Pilot Study". Frontiers in nutrition doi:10.3389/fnut.2021.650053

elsevier.es

Sandoval-Avila S, Diaz NF, Gómez-Pinedo U, Canales-Aguirre AA, Gutiérrez-Mercado YK, Padilla-Camberos E, Marquez-Aguirre AL, Díaz-Martínez NE (2016). "Efecto neuroprotector de fitoquímicos en cultivo de neuronas dopaminérgicas". Neurologia S0213-4853 (16): 30077-9 (Hispanice)

futuremedicine.com

Pinto S, Velay JL (2015). "Handwriting as a marker for PD progression: a shift in paradigm". Neurodegener Dis Manag: 367-9

hieronymus.us.com

In David Morgan, Vocabularium Latinum (20 Decembris 2010).

michaeljfox.org

Nexus ad situm Operis Fundati Michaeli J. Fox Indagationis Morbi Parkinsoniani

movementdisorders.org

Galvez-Jimenez N, Lugo-Sanchez R, Khan T (2017): Autonomic Issues in Parkinson's Disease, Societas Internationalis Pertubationum Motuumque Parkinsonianorum (MDS)

nih.gov

pubmed.ncbi.nlm.nih.gov

Espay A. J., Kalia L. V., Gan-Or Z., Williams-Gray C. H., Bedard P. L., Rowe S. M., Morgante F., Fasano A., Stecher B., Kauffman M. A., et al. (Mar 2020). "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?". Neurology 94 (11): 481-94 doi:10.1212/WNL.0000000000009107
Kalia L. V., Lang A. E. (August 2015). "Parkinson's disease". Lancet 386 (9996): 896-912 doi:10.1016/S0140-6736(14)61393-3
Kim C.Y., Alcalay R.N. (Apr 2017). "Genetic Forms of Parkinson's Disease". Seminars in neurology 37 (2): 135-46 doi:10.1055/s-0037-1601567
Cook L., Schulze J., Kopil C., Hastings T., Naito A., Wojcieszek J., Payne K., Alcalay R. N., Klein C., Saunders-Pullman R., Simuni T., Foroud T. (Feb 2021). "Genetic Testing for Parkinson Disease: Are We Ready?". Neurology. Clinical practice 11 (1): 69-77 doi:10.1212/CPJ.0000000000000831
Lwin A., Orvisky E., et al. (Ian 2004). "Glucocerebrosidase mutations in subjects with parkinsonism". Molecular genetics and metabolism 81 (1): 70-3
García-Sanz P., Aerts J. M. F. G., Moratalla R. (Mai 2021). "The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease". Movement disorders 36 (5): 1070-85
Deng H., Wang P., Jankovic J. (Mar 2018). "The genetics of Parkinson disease". Ageing research reviews 42: 72-85
Vilariño-Güell C., Wider C., et al. (Iul 2011). "VPS35 mutations in Parkinson disease". American journal of human genetics 89 (1): 162-7
Do J., McKinney C., Sharma P., Sidransky E. (Aug 2019). "Glucocerebrosidase and its relevance to Parkinson disease". Molecular neurodegeneration 14 (1): 36
Migdalska-Richards A., Daly L., Bezard E., Schapira A. H. V. (Nov 2016). "Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice". Annals of neurology 80 (5): 766-75
Mullin S., Smith L., Lee K., D'Souza G., Woodgate P., Elflein J., Hällqvist J., Toffoli M., Streeter A., Hosking J., Heywood W. E., Khengar R., Campbell P., Hehir J., Cable S., Mills K., Zetterberg H., Limousin P., Libri V., Foltynie T., Schapira A. H. V. (Apr 2020). "Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial". JAMA neurology 77 (4): 427-34
Coppedè F. (2012). "Genetics and Epigenetics of Parkinson's Disease". The scientific world journal .
Zhang Y., Shu L. (Oct 2018). "A Comprehensive Analysis of the Association Between SNCA Polymorphisms and the Risk of Parkinson's Disease". Frontiers in molecular neuroscience 11: 391 .
Pereira S. L., Grossmann D., Delcambre S., Hermann A., Grünewald A. (Iun 2023). "Novel insights into Parkin-mediated mitochondrial dysfunction and neuroinflammation in Parkinson's disease". Current opinion in neurobiology doi:10.1016/j.conb.2023.102720
Mizuno Y. (Oct 2020). "More than 20 years of the discovery of Park2". Neuroscience research doi:10.1016/j.neures.2020.02.002
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (Oct 1998). "The ubiquitin pathway in Parkinson's disease". Nature 395 (6701): 451-2 doi:10.1038/26652
Healy, D. G., Abou-Sleiman, P. M., Casas, J. P., Ahmadi, K. R., Lynch, T., Gandhi, S., Muqit, M. M. K., Foltynie, T., Barker, R., Bhatia, K. P., et al. (Apr 2006). "UCHL-1 is not a Parkinson's disease susceptibility gene". Annals of neurology 59 (4): 627-33 doi:10.1002/ana.20757
Nielsen P. Y. Ø., Okarmus J., Meyer M. (Feb 2023). "Role of Deubiquitinases in Parkinson's Disease-Therapeutic Perspectives". Cells 12 (4): 651 doi:10.3390/cells12040651
Skipper L., Li Y., Bonnard C., Pavanni R., Yih Y., Chua E., Sung W.-K., Tan L., Wong M.-C., Tan E.-K., Liu J. (Dec 2005). "Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease". Human molecular genetics 14 (23): 3549-56
Papapetropoulos S., Singer C., Ross O. A., Toft M., Johnson J. L., Farrer M. J., Mash D. C. (Sep 2006). "Clinical heterogeneity of the LRRK2 G2019S mutation". Archives of neurology 63 (9): 1242-6
Dächsel J. C., Ross O. A., Mata I. F., Kachergus J., Toft M., Cannon A., Baker M., Adamson J., Hutton M., Dickson D. W., Farrer M. J. (Mai 2007). "Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions". Acta neuropathologica 113 (5): 601-6
Hayashi C., Suzuki N., et al. (Feb 2020). "The extracellular domain of teneurin-4 promotes cell adhesion for oligodendrocyte differentiation". Biochemical and biophysical research communications 523 (1): 171-6
Pu J.-L., Gao T., et al. (Dec 2020). "Parkinson's Disease in Teneurin Transmembrane Protein 4 ( TENM4) Mutation Carriers". Frontiers in genetics 11: 598064. doi: 10.3389/fgene.2020.598064. eCollection 2020
Chen X., Kordich J. K., et al. (Mar 2019). "Parkinson's disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration". Proceedings of the National Academy of Sciences of the United States of America 116 (12): 5765-74
Ma L.-Y., Liu G.-L., Wang D.-X-, Zhang M.-M., Kou W.-Y., Feng T. (Feb 2019). "Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease". ACS chemical neuroscience 10 (2): 861-79
Braak H., De Vos R. A., Bohl J., Del Tredici K. (2006). "Gastic 𝛼-synuclein immunoresctive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology". Neuroscience Letters 396 (1): 67-72
Chao Y.-X., Gulam M. Y., et al. (Feb 2020). "Gut-Brain Axis: Potential Factors Involved in the Pathogenesis of Parkinson's Disease". Frontiers in neurology 11: 849
Holec S. A. M., Woerman A. L. (Mai 2020). "Evidence of Distinct α-Synuclein Strains Underlying Disease Heterogeneity". Acta neuropathologica .
El-Agnaf O. M. A., Salem S. A., et al. (Oct 2003). "Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma". FASEB journal 17 (13): 1945-7
Besong-Agbo D., Wolf E., et al. (Ian 2013). "Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease". Neurology 80 (2): 169-75
Wang J., Zheng B., et al. (Sep 2020). "Differential Circulating Levels of Naturally Occurring Antibody to α-Synuclein in Parkinson's Disease Dementia, Alzheimer's Disease, and Vascular Dementia". Frontiers in aging neuroscience 12: 571437
Wilson J., Yarnall A. J., et al. (Mar 2021). "Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease". Movement disorders 36 (3): 611-21
Van der Zee S., Müller M. L. T. M., et al. (Mar 2021). "Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease". Movement disorders 36 (3): 642-50
Doty R. L. (Mai 2012). "Olfactory dysfunction in Parkinson disease". Nature reviews. Neurology 8 (6): 329-39
Sheng M.-Z., Fang T.-C., Chen Y.-H., Chang M.-H., Yang C.-P., Lin C.-H. (Iun 2021). "Is either anosmia or constipation associated with cognitive dysfunction in Parkinson's disease?". PLoS One 16 (6): e0252451
Svensson E., Horváth-Puhó E., Thomsen R. W., Djurhuus J. C., Pedersen L., Borghammer P., Sørensen H. T. (Oct 2015). "Vagotomy and subsequent risk of Parkinson's disease". Annals of neurology (4): 522-9 doi:10.1002/ana.24448
Gries M., Christmann A., Schulte S., Weyland M., Rommel S., Martin M., Baller M., Röth R., Schmitteckert S., Unger M., Liu Y., Sommer F., Mühlhaus T., Schroda M., Timmermans J.-P., Pintelon I., Rappold G. A., Britschgi M., Lashuel H., Menger M. D., Laschke M. W., Niesler B., Schäfer K.-H. (Iun 2021). "Parkinson mice show functional and molecular changes in the gut long before motoric disease onset". Molecular neurodegeneration 16 (1): 34
Mulak A., Bonaz B. (Oct 2015). "Brain-gut-microbiota axis in Parkinson's disease". World journal of gastroenterology 21 (37): 10609-20
Thomzig A., Wagenführ K., Pinder P., Joncic M., Schulz-Schaeffer W. J., Beekes M. (Iun 2021). "Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease". Acta neuropathologica 141 (6): 861-79
Gronich N., Abernethy D. R., et al. (Sep 2018). "β2-adrenoceptor agonists and antagonists and risk of Parkinson's disease". Movement disorders 33 (9): 1465-71
Jo S., Kim Y.-J., Park K. W., Hwang Y. S., Lee S. H., Kim B. J., Chung S. J. (Iul 2021). "Association of NO2 and Other Air Pollution Exposures With the Risk of Parkinson Disease". JAMA neurology 78 (7): 800-8 doi:10.1001/jamaneurol.2021.1335
Srivanitchapoom P., Hallett M. (Ian 2016). "Camptocormia in Parkinson's disease: definition, epidemiology, pathogenesis and treatment modal". Journal of neurology, neurosurgery, and psychiatriy 87 (1): 75-85
Azher S. N., Jankovic J. (Aug 2005). "Camptocormia: pathogenesis, classification, and response to therapy". Neurology 65 (3): 355-9
Ponfick M., Gdynia H.-J., et al. (2011). "Camptocormia in Parkinson's disease: a review of the literature". Neuro-degenerative diseases 8 (5): 283-8
Fasano A., Geroin C., et al. (Aug 2018). "Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal". Parkinsonism & related disorders 53: 53-7
Margraf N. G., Wrede A., et al. (Iun 2016). "Pathophysiological Concepts and Treatment of Camptocormia". Journal of Parkinson's disease 6 (3): 485-501
Pinto S., Ghio A., Teston B., Viallet F. (2010). "La dysarthrie au cours de la maladie de Parkinson. Histoire naturelle de ses composantes : dysphonie, dysprosodie et dysarthrie". Revue neurologique 166 (10): 800-10 doi:10.1016/j.neurol.2010.07.005
Elfil M., Kamel S., et al. (Iun 2020). "Implications of the Gut Microbiome in Parkinson's Disease". Movement disorders 35 (6): 921-33
Huang Y., Liao J., Liu X., Zhong Y., Cai X., Long L. (Apr 2021). "Review: The Role of Intestinal Dysbiosis in Parkinson's Disease". Frontiers in cellular and infection microbiology 11: 615075
Bhidayasiri R., Phuenpathom W., Tan A. H., Leta V., Phumphid S., Chaudhuri K. R., Pal P. K. (Aug 2022). "Management of dysphagia and gastroparesis in Parkinson's disease in real-world clinical practice - Balancing pharmacological and non-pharmacological approaches". Frontiers in Aging Neuroscience 14 doi:10.3389/fnagi.2022.979826
Sakakibara R., Panicker J., Finazzi-Agro E., Iacovelli V., Bruschini H., et al. (Iun 2016). "A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders". Neurourology and urodynamics 35 (5): 551-63 doi:10.1002/nau.22764
Devos D., Lebouvier T., Lardeux B., Biraud M., Rouaud T., Pouclet H., Coron E., Bruley des Varannes S., Naveilhan P., Nguyen J.-M., Neunlist M., Derkinderen P. (Feb 2013). "Colonic inflammation in Parkinson's disease". Neurobiology of disease 50: 42-8
Knudsen K., Krogh K., Østergaard K., Borghammer P. (2017 month=Ian). "Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives". Movement disorders 32 (1): 94-105 doi:10.1002/mds.26866
Borm C. D. J. M., Visser F., et al. (Apr 2020). "Seeing Ophthalmologic Problems in Parkinson Disease: Results of a Visual Impairment Questionnaire". Neurology 94 (14): e1539-47
Fullard M. E., Morley J. F., Duda J. E. (Oct 2017). "Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease". Neuroscience Bulletin 33 (5): 515-25
Patterson L., Rushton S. P., Attems J., Thomas A. J,, Morris C. M. (Iul 2019). "Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders". Brain pathology (4): 544-57 doi:10.1111/bpa.12697
Emre M., Aarsland D., et al. (Sep 2007). "Clinical diagnostic criteria for dementia associated with Parkinson's disease". Movement disorders 22 (12): 1689-707
Swann P., O'Brien J. T. (Iun 2019). "Management of visual hallucinations in dementia and Parkinson's disease". International psychogeriatrics 31 (6): 815-36
Kang J.-H., Irwin D. J., et al. (Oct 2013). "Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease". JAMA Neurology 70 (10): 1277-87
Nyholm D., Lennernäs H. (Feb 2008). "Irregular gastrointestinal drug absorption in Parkinson's disease". Expert Opinion on drug metabolism & toxicology 4 (2): 193-203 doi:10.1517/17425255.4.2.193
Chaudhuri K. R., Poewe W., Brooks D. (Iul 2018). Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. 33. pp. 909-19 doi:10.1002/mds.27386
Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. (Ian 2007). "Valvular heart disease and the use of dopamine agonists for Parkinson's disease". The New England journal of medicine 356 (1): 39-46 doi:10.1056/NEJMoa054830
Brocks D. R. (Mai-Aug 1999). "Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective". Journal of pharmacy & pharmaceutical sciences 2 (2): 39-46
Welsh T. J., Van der Wardt V., et al. (Iun 2018). "Anticholinergic Drug Burden Tools/Scales and Adverse Outcomes in Different Clinical Settings: A Systematic Review of Reviews". Drugs & aging 35 (6): 523-38
Gray R., Patel S., Ives N., Rick C., Woolley C., Muzerengi S., Gray A., Jenkinson C., McIntosh E., Wheatley K. et al. (Februarius 2022). "Long-term Effectiveness of Adjuvant Treatment with Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared with Dopamine Agonists among Patients with Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial". JAMA Neurology 79 (2): 131-40 . doi:10.1001/jamaneurol.2021.4736.
Schneeberger A., Mandler M., et al. (Ianuarius 2012). "Vaccination for Parkinson's disease". Parkinsonism & related disorders 18 supplementum: S11-3 .
Volc D., Poewe W., et al. (Iul 2020). "Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial". The Lancet, neurology 19 (7): 591-600
Meissner W. G., Pavy-Le Traon A., et al. (Nov 2020). "A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy". Movement disorders 35 (11): 1957-65
Lu C.-S., Chang H.-C., Weng Y.-H., Chen C.-C., Kuo Y.-S., Tsai Y.-C. (Iun 2021). "The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson's Disease: A Pilot Study". Frontiers in nutrition doi:10.3389/fnut.2021.650053
Franke C., Alexander Storch A. (2017). "Nonmotor Fluctuations in Parkinson's Disease". International reviel of neurobiology 134: 947-71
Elfil M., Bahbah E. I., et al. (Mar 2021). "Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease". Movement disorders 36 (3): 570-80
Seidl S. E., Santiago J. A., et al. (Mar 2014). "The emerging role of nutrition in Parkinson's disease". Frontiers in aging neuroscience 6 (36): doi: 10.3389/fnagi.2014.00036

ncbi.nlm.nih.gov

GBD 2016 Parkinson's Disease Collaborators (2018). "Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016". Lancet neurology 17 (11): 939-53 .
Coppedè F (2012). "Genetics and epigenetics of Parkinson's disease". ScientificWorldJournal 489830 .
Braak H., Del Tredici K., Rüb U., de Vos R. A., Jansen Steur E. N., Braak E. (Mar-Apr 2003). "Staging of brain pathology related to sporadic Parkinson's disease". Neurobiology of aging 24 (2): 197-211
Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D., Rüb U. (Oct 2002). "Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)". Journal of neurology 249 (Suppl. 3): 1-5
Anselmi L., Toti L., Bove 1., Hampton J., Travagli R. A. (2017). "A Nigro-Vagal Pathway Controls Gastric Motility and Is Affected in a Rat Model of Parkinsonism". Gastroenterology 153 (6): 1581-93
Lysen T. S., Darweesh S. K. L., Ikram M. K., Luik A. I., Ikram M. A. (Iul 2019). "Sleep and risk of parkinsonism and Parkinson's disease: a population-based study". Brain 142 (7): 2013-22 doi:10.1093/brain/awz113
Kummer B. R., Diaz I., Wu X., Aaroe A. E., Chen M. L., Iadecola C., Kamel H., Navi B. B. (4 2019). "Associations between cerebrovascular risk factors and parkinson disease". Annals of neurology 86 (4): 572-81 .
Gironell A., Pascual-Sedano B., Aracil I., Marín-Lahoz J., Pagonabarraga J., Kulisevsky J. (2018). "Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification". Parkinson's disease: doi: 10.1155/2018/4327597
Mukherjee A., Biswas A., Das S. K. (2016). "Gut dysfunction in Parkinson's disease". World journal of gastroenterology 22 (25): 5742-52
Hatsuta H. Takao M., Nakano Y., Nogami A., Uchino A., Sumikura H., Kanemaru K., Arai T., Itoh Y., Murayama S. (2016). "Reduction of Small Fibers of Thoracic Ventral Roots and Neurons of Intermediolateral Nucleus in Parkinson Disease and Dementia with Lewy Bodies". Journal of Parkinson's disease 6 (2): 325-34
Snider S. R., Fahn S., Isgreen W. P., Cote L. J. (1976). "Primary sensory symptoms in parkinsonism". Neurology 26 (5): 423-9
Valek L., Auburger G., Tegeder I. (Iun 2019). "Sensory neuropathy and nociception in rodent models of Parkinson's disease". Disease models & mechanism 12 (6): pii: dmm039396
Rukavina K., Leta V., Sportelli C., Buhidma Y., Duty S., Malcangio M., Ray Chaudhuri K. (Aug 2019). "Pain in Parkinson's disease: new concepts in pathogenesis and treatment". Current opinion in neurology 32 (4): 579-88
Renoux C, Dell'Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P (2016). "Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease". Br J Clin Pharmacol 82 (2): 461-72
Powell A., Ireland C., Lewis S. J. G. (Mai 2020). "Visual Hallucinations and the Role of Medications in Parkinson's Disease: Triggers, Pathophysiology, and Management". The journal of neuropsychiatry and clinical neurosciences: appineuropsych19110316
Levin J., Kurz A., Arzberger T., Giese A., Höglinger G. U. (2016). "The Differential Diagnosis and Treatment of Atypical Parkinsonism". Dtsch Arztebl Int 113 (5): 61-9
Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O'Connell M, Gupta S; IPX066 ADVANCE-PD investigators (2013). "Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial". Lancet Neurol 12 (4): 346-56
Schapira A. H. (2011). "Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects". CNS Drugs 25 (12): 1061-71
Stocchi F., Arnold G., Onofrj M., Kwiecinski H., Szczudlik A., Thomas A., Bonuccelli U., Van Dijk A., Cattaneo C., Sala P., Fariello R. G.; Safinamide Parkinson's Study Group (2004). "Improvement of motor function in early Parkinson disease by safinamide". Neurology 63 (4): 746-8
Schwab RS, England AC Jr, Poskanzer DC, Young RR (1969). "Amantadine in the treatment of Parkinson's disease". JAMA 208 (7): 1168-70
Dungo R., Deeks E. D. (Iun 2013). "Istradefylline: first global approval". Drugs 73 (8): 875-82
Jankovic J., Goodman I., Safirstein B., Marmon T. K., Schenk D. B., Koller M., Zago W., Ness D. K., Griffith S. G., Grundman M., Soto J., Ostrowitzki S., Boess F. G., Martin-Facklam M., Quinn J. F., Isaacson S. H., Omidvar O., Ellenbogen A., Kinney G. G. (2018). "Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients with Parkinson Disease: A Randomized Clinical Trial". JAMA Neurol: doi: 10.1001/jamaneurol.2018.1487 .
Muthuraman M., Koirala N., Ciolac D., Pintea B., Glaser M., Groppa S., Tamás G., Groppa S. (2018). "Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease". Frontiers in neurology 9: 711 .
Higginson I. J., Gao W., Saleem T. Z., Chaudhuri K. R., Burman R., McCrone P., Leigh P. N. (2012). "Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors". PLoS one 7 (11): e46327
Gagne JJ, Power MC (2010). "Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis". Neurology 74 (12): 995-1002 .
de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM (2006). "Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease". Neurology 67 (2): 315-8 .
Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group (2002). "Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline". Arch Neurol 59 (10): 1541-50

ovid.com

insights.ovid.com

Reichmann H., Brandt M. D., Klingelhoefer L (aug 2016). "The nonmotor features of Parkinson's disease: pathophysiology and management advances". Current opinion in neurology 29 (4): 467-73

parkinsonnet.info

ParkinsonNet et societas Batavica physiotherapiae de physiotherapia et morbo Parkinson. (Anglice)

springer.com

link.springer.com

Rosborough K., Patel N., Kalia L. V. (2017). "α-Synuclein and Parkinsonism: Updates and Future Perspectives". Curr Neurol Neurosci Rep 17 (4): 31

stetoskop.info

"Morbus Parkinson . . . Parkinsonismus secundarius [etc.]": vide G20-G26 apud Stetoskop.

tandfonline.com

Müller T (6 2013). "Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease". Expert Rev Neurother 13: 707-18

wikipedia.org

en.wikipedia.org

Espay A. J., Kalia L. V., Gan-Or Z., Williams-Gray C. H., Bedard P. L., Rowe S. M., Morgante F., Fasano A., Stecher B., Kauffman M. A., et al. (Mar 2020). "Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?". Neurology 94 (11): 481-94 doi:10.1212/WNL.0000000000009107
Kalia L. V., Lang A. E. (August 2015). "Parkinson's disease". Lancet 386 (9996): 896-912 doi:10.1016/S0140-6736(14)61393-3
Kim C.Y., Alcalay R.N. (Apr 2017). "Genetic Forms of Parkinson's Disease". Seminars in neurology 37 (2): 135-46 doi:10.1055/s-0037-1601567
Cook L., Schulze J., Kopil C., Hastings T., Naito A., Wojcieszek J., Payne K., Alcalay R. N., Klein C., Saunders-Pullman R., Simuni T., Foroud T. (Feb 2021). "Genetic Testing for Parkinson Disease: Are We Ready?". Neurology. Clinical practice 11 (1): 69-77 doi:10.1212/CPJ.0000000000000831
Pereira S. L., Grossmann D., Delcambre S., Hermann A., Grünewald A. (Iun 2023). "Novel insights into Parkin-mediated mitochondrial dysfunction and neuroinflammation in Parkinson's disease". Current opinion in neurobiology doi:10.1016/j.conb.2023.102720
Mizuno Y. (Oct 2020). "More than 20 years of the discovery of Park2". Neuroscience research doi:10.1016/j.neures.2020.02.002
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (Oct 1998). "The ubiquitin pathway in Parkinson's disease". Nature 395 (6701): 451-2 doi:10.1038/26652
Healy, D. G., Abou-Sleiman, P. M., Casas, J. P., Ahmadi, K. R., Lynch, T., Gandhi, S., Muqit, M. M. K., Foltynie, T., Barker, R., Bhatia, K. P., et al. (Apr 2006). "UCHL-1 is not a Parkinson's disease susceptibility gene". Annals of neurology 59 (4): 627-33 doi:10.1002/ana.20757
Nielsen P. Y. Ø., Okarmus J., Meyer M. (Feb 2023). "Role of Deubiquitinases in Parkinson's Disease-Therapeutic Perspectives". Cells 12 (4): 651 doi:10.3390/cells12040651
Svensson E., Horváth-Puhó E., Thomsen R. W., Djurhuus J. C., Pedersen L., Borghammer P., Sørensen H. T. (Oct 2015). "Vagotomy and subsequent risk of Parkinson's disease". Annals of neurology (4): 522-9 doi:10.1002/ana.24448
Lysen T. S., Darweesh S. K. L., Ikram M. K., Luik A. I., Ikram M. A. (Iul 2019). "Sleep and risk of parkinsonism and Parkinson's disease: a population-based study". Brain 142 (7): 2013-22 doi:10.1093/brain/awz113
Jo S., Kim Y.-J., Park K. W., Hwang Y. S., Lee S. H., Kim B. J., Chung S. J. (Iul 2021). "Association of NO2 and Other Air Pollution Exposures With the Risk of Parkinson Disease". JAMA neurology 78 (7): 800-8 doi:10.1001/jamaneurol.2021.1335
Pinto S., Ghio A., Teston B., Viallet F. (2010). "La dysarthrie au cours de la maladie de Parkinson. Histoire naturelle de ses composantes : dysphonie, dysprosodie et dysarthrie". Revue neurologique 166 (10): 800-10 doi:10.1016/j.neurol.2010.07.005
Bhidayasiri R., Phuenpathom W., Tan A. H., Leta V., Phumphid S., Chaudhuri K. R., Pal P. K. (Aug 2022). "Management of dysphagia and gastroparesis in Parkinson's disease in real-world clinical practice - Balancing pharmacological and non-pharmacological approaches". Frontiers in Aging Neuroscience 14 doi:10.3389/fnagi.2022.979826
Sakakibara R., Panicker J., Finazzi-Agro E., Iacovelli V., Bruschini H., et al. (Iun 2016). "A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders". Neurourology and urodynamics 35 (5): 551-63 doi:10.1002/nau.22764
Knudsen K., Krogh K., Østergaard K., Borghammer P. (2017 month=Ian). "Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives". Movement disorders 32 (1): 94-105 doi:10.1002/mds.26866
Patterson L., Rushton S. P., Attems J., Thomas A. J,, Morris C. M. (Iul 2019). "Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders". Brain pathology (4): 544-57 doi:10.1111/bpa.12697
Nyholm D., Lennernäs H. (Feb 2008). "Irregular gastrointestinal drug absorption in Parkinson's disease". Expert Opinion on drug metabolism & toxicology 4 (2): 193-203 doi:10.1517/17425255.4.2.193
Chaudhuri K. R., Poewe W., Brooks D. (Iul 2018). Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. 33. pp. 909-19 doi:10.1002/mds.27386
Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. (Ian 2007). "Valvular heart disease and the use of dopamine agonists for Parkinson's disease". The New England journal of medicine 356 (1): 39-46 doi:10.1056/NEJMoa054830
Gray R., Patel S., Ives N., Rick C., Woolley C., Muzerengi S., Gray A., Jenkinson C., McIntosh E., Wheatley K. et al. (Februarius 2022). "Long-term Effectiveness of Adjuvant Treatment with Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared with Dopamine Agonists among Patients with Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial". JAMA Neurology 79 (2): 131-40 . doi:10.1001/jamaneurol.2021.4736.
Lu C.-S., Chang H.-C., Weng Y.-H., Chen C.-C., Kuo Y.-S., Tsai Y.-C. (Iun 2021). "The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson's Disease: A Pilot Study". Frontiers in nutrition doi:10.3389/fnut.2021.650053

wiley.com

onlinelibrary.wiley.com

Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Del Dotto P (Nov. 2009). "The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease". Mov Disord 24: 1641-9
Broen M. P., Braaksma M. M., Patijn J., Weber W. E. (4 2012). "Prevalence of pain in Parkinson's disease: a systematic Review using the modified QUADAS tool". Mov Disord 27: 480-4
Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, et al. (Oct 2015). "MDS research criteria for prodromal Parkinson's disease". Mov Disord 30: 1600-11